Breaking News

NEMUS, Catalent to Advance NB1222 for Clinical Trials

Will advance development of a human-dosage suppository formulation of NB1222, a prodrug of synthetically manufactured THC

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

NEMUS Bioscience, Inc. and partner Catalent Pharma Solutions will advance development of a human-dosage suppository formulation of NB1222, the prodrug of tetrahydrocannabinol (THC). NB1222, also known as THC-valine-hemisuccinate, is being developed for the treatment and management of chemotherapy-induced nausea and vomiting (CINV). NB1222 is synthetically manufactured and is not plant-derived. “Nemus is looking forward to working with Catalent to complete this important milestone as th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters